189 related articles for article (PubMed ID: 10623331)
1. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system.
Ross DL; Gabrio BJ
J Aerosol Med; 1999; 12(3):151-60. PubMed ID: 10623331
[TBL] [Abstract][Full Text] [Related]
2. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.
Boccuzzi SJ; Wogen J; Roehm JB
Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983
[TBL] [Abstract][Full Text] [Related]
3. The change to non-CFC metered dose inhalers.
Rubinfeld A
Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
[TBL] [Abstract][Full Text] [Related]
4. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol.
Peyron ID; Britto IL; Benissan LB; Tardieu BZ
Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605
[TBL] [Abstract][Full Text] [Related]
5. Switching to CFC-free beclometasone for asthma.
Drug Ther Bull; 2008 Jun; 46(6):46-8. PubMed ID: 18525059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P
Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604
[TBL] [Abstract][Full Text] [Related]
7. Combining a positive expiratory pressure device with a metered-dose inhaler reservoir system using chlorofluorocarbon albuterol and hydrofluoroalkane albuterol: effect on dose and particle size distributions.
Rau JL; Torniainen M
Respir Care; 2000 Mar; 45(3):320-6. PubMed ID: 10771801
[TBL] [Abstract][Full Text] [Related]
8. Awareness of the ozone layer and acceptance of a new CFC-free metered dose inhaler among asthmatic patients.
Liam CK; Lim KH
Int J Tuberc Lung Dis; 1998 Aug; 2(8):683-9. PubMed ID: 9712285
[TBL] [Abstract][Full Text] [Related]
9. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
Bronsky E; Ekholm BP; Klinger NM; Colice GL
J Asthma; 1999; 36(1):107-14. PubMed ID: 10077140
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO.
Huchon G; Hofbauer P; Cannizzaro G; Iacono P; Wald F
Eur Respir J; 2000 Apr; 15(4):663-9. PubMed ID: 10780756
[TBL] [Abstract][Full Text] [Related]
11. Plume temperature emitted from metered dose inhalers.
Brambilla G; Church T; Lewis D; Meakin B
Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465
[TBL] [Abstract][Full Text] [Related]
12. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma.
Dockhorn R; Vanden Burgt JA; Ekholm BP; Donnell D; Cullen MT
J Allergy Clin Immunol; 1995 Jul; 96(1):50-6. PubMed ID: 7622763
[TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroid delivery systems: clinical role of a breath-actuated device.
Donnell D
Eur Rev Med Pharmacol Sci; 2001; 5(1):7-16. PubMed ID: 11860222
[TBL] [Abstract][Full Text] [Related]
14. Chlorofluorocarbon-free inhalation devices in asthma: are there clinical implications?
Ruffin RE; Southcott AM
BioDrugs; 1998 Aug; 10(2):91-6. PubMed ID: 18020587
[TBL] [Abstract][Full Text] [Related]
15. Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.
Hughes DA; Woodcock A; Walley T
Thorax; 1999 Dec; 54(12):1087-92. PubMed ID: 10567628
[TBL] [Abstract][Full Text] [Related]
16. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler.
Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J
Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial.
Blumenthal MN; Casale TB; Fink JN; Uryniak T; Casty FE
J Allergy Clin Immunol; 1998 Jan; 101(1 Pt 1):7-13. PubMed ID: 9449494
[TBL] [Abstract][Full Text] [Related]
18. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
Mackie AE; McDowall JE; Ventresca P; Bye A; Falcoz C; Daley-Yates PT
Clin Pharmacokinet; 2000; 39 Suppl 1():17-22. PubMed ID: 11140429
[TBL] [Abstract][Full Text] [Related]
19. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
[TBL] [Abstract][Full Text] [Related]
20. Issues surrounding MDI formulation development with non-CFC propellants.
Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
